Executive Summary
CMS's expanded TAVR coverage is reshaping the referral funnel before the trial data catches up. The TCT 2026 late-breaker slate — PROGRESS (TAVR vs surveillance in moderate AS, NEJM), TRAVEL III (LuX-Valve Plus in severe TR, Circulation), and CLASP II TR (PASCAL, NEJM) — will decide whether that expansion is evidence-based or aspirational. A National Inpatient Sample analysis in Structural Heart shows women undergoing M-TEER suffer more tamponade, bleeding, and transfusion than men across 64,905 hospitalizations. A novel invasive hemodynamic marker (V') from the same journal flags residual MR risk post-TEER with a 3-fold hazard for death or HF hospitalization. Transcatheter volumes are rising while the field has not answered the durability, sex-disparity, and patient-selection questions that would justify the expansion.
- Women make up 45.8% of US TEER recipients and face higher tamponade and bleeding despite equivalent mortality — a signal the field cannot keep ignoring (Structural Heart, NIS 2016–2022).
- Post-M-TEER V' >13 mmHg predicts a 3.01-fold hazard of HF hospitalization or death, offering an intraprocedural checkpoint beyond echo (Structural Heart, N=231).
- Ultra-rapid outpatient TAVI for acute valve syndrome cut length of stay from 20 to 12 days with no excess pre-procedure death (Open Heart, N=183).
- CT-based radiomics of aortic calcium bumped paravalvular regurgitation prediction AUC from 0.76 to 0.84 in a 393-patient multicenter cohort (JCCT).
- Medical societies and aging advocates issued early — and mixed — reactions to broader CMS TAVR coverage, foreshadowing appropriateness scrutiny (Cardiovascular Business).
What to watch: TCT 2026 in San Diego (Oct 31–Nov 3) with PROGRESS, TRAVEL III, CLASP II TR, ENCIRCLE 2-year, JENA-VAD, and the EARLY TAVR cost-effectiveness readout — a single week that will reset the guideline conversation across all three valves.
Aortic Valve (TAVR/TAVI)
Two operational papers land today alongside a case report that belongs in every TAVR operator's inbox. The Open Heart ultra-rapid outpatient pathway (single-center, N=183, pre/post design — not randomized) shows 55% of acute valve syndrome patients can be safely discharged for outpatient TAVI within two weeks, saving 210 bed-days with no excess death (6.9% vs 6.4% pre-procedure event rate). A JCCT multicenter radiomics study (N=393) demonstrates CT calcium texture features improve significant PVR prediction from AUC 0.76 to 0.84 — meaningful, but requiring software adoption and prospective validation before it changes workflow. Neither paper addresses the core guideline question: ACC/AHA 2020 and ESC 2025 both favor SAVR for low-surgical-risk patients under 65–70, and no operational efficiency data shifts that recommendation.
The cautionary tale: a JACC Case Reports patient developed 71 seconds of asystole five days post-TAVR despite paradoxical QRS narrowing and no inpatient high-grade AV block, driven by His-bundle injury with phase 4 block. Ambulatory monitoring caught what telemetry missed — a workflow gap, not a device gap, but one that costs lives when missed. A separate CCI series (N=23, single-center) shows Sapien TAVR is feasible after prior endovascular aortic stent grafts — hypothesis-generating only at this sample size.
Mitral Valve (MitraClip, PASCAL, TMVR)
[NOTABLE] The sex-disparity signal in TEER just got harder to dismiss. The Structural Heart NIS analysis of 64,905 US TEER hospitalizations (2016–2022) shows women — 45.8% of recipients — experience higher tamponade, major bleeding, transfusion, and nonhome discharge than men, with equivalent adjusted mortality (aOR 0.96). Women were also half as likely to receive in-hospital ICD/CRT-D (aOR 0.46). Administrative data with etiology proxy strata limit causal inference; a prospective look is overdue regardless. Surgical MV repair — Class I in both ACC/AHA 2020 and ESC 2025 for primary MR, and per ESC 2025 Class I in asymptomatic patients meeting the AF/SPAP/LA/TR threshold criteria — carries no comparable sex-disparity signal in the published surgical literature, which sharpens the question about TEER-specific procedural risk in women.
The V' hemodynamic parameter (V-wave minus mean LA pressure, N=231) offers a concrete intraprocedural metric: post-TEER V' >13 mmHg carried HR 3.01 (95% CI 1.68–5.4) for HF hospitalization or death. Single-center and retrospective — the physiology is sound, and it echoes the field's long-standing discomfort with echo-only adjudication of residual MR. TEER for ventricular secondary MR is ACC/AHA 2020 Class IIa and ESC 2025 Class I, LOE A for COAPT-eligible patients; V' could sharpen intraoperative endpoint definition in both populations. ENCIRCLE's 2-year TMVR readout at TCT is the next real durability test for transcatheter mitral replacement.
Tricuspid Valve (TriClip, TTVR)
No original tricuspid data today, but TCT 2026's slate is the story. Three tricuspid trials read out in San Diego: TRAVEL III (LuX-Valve Plus TTVR vs medical therapy, Circulation), CLASP II TR (PASCAL vs medical therapy, NEJM), and a TRIC-I-HF-DZHK24 subgroup analysis, alongside Hahn's 180,977-patient community TR epidemiology cohort. ESC 2025 already elevated transcatheter TV treatment to Class IIa, LOE A on the strength of TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II; ACC/AHA 2020 offers no comparable recommendation. If CLASP II TR delivers a durable hard-endpoint signal — not just QoL and HF hospitalization reduction — the ACC/AHA gap becomes untenable. The surgical counterpoint is not abstract: ESC 2025 upgraded TV surgery for symptomatic primary TR to Class I, and both guidelines retain Class I for concomitant TV repair during left-sided operations. The right-sided revolution is not a transcatheter monopoly.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. Two upcoming TCT readouts will drive the comparison: a Chinese multicenter RCT of TAVR vs SAVR for symptomatic severe AR (JAMA collaboration), and the JENA-VAD study of the JenaValve Trilogy in LVAD patients with AR. Per ESC 2025, TAVI for AR is Class IIb for inoperable patients only; a positive AR RCT would be the first level-1 evidence to move that recommendation. SAVR remains Class I for symptomatic severe AR in both guidelines.
Device & Technology
The JCCT radiomics work is the day's clearest technology story: calcium texture, not just volume, predicts sealing. Expect vendors to integrate this into pre-procedural planning software within 18 months; the open question is whether it changes valve sizing decisions or produces better-informed consent without changing the implant strategy. The His-bundle case reinforces the need for structured post-TAVR ambulatory monitoring — a workflow gap, not a device gap, but one that costs lives when missed.
Regulatory & Policy
Broader CMS TAVR coverage drew early reactions from medical societies and aging advocates, per Cardiovascular Business. The tension is familiar: access advocates cheer, appropriateness watchers worry. Neither ACC/AHA 2020 nor ESC 2025 supports broad TAVR use outside guideline-defined severe AS. PROGRESS at TCT will be the first RCT to address whether moderate AS should enter the conversation at all.
Industry & Market
Incheon St. Mary's Hospital in Korea performed the region's first TMVR in an octogenarian, per Korea Biomedical Review — a marker of continued Asia-Pacific TMVR diffusion despite the technology's ongoing struggle for a durable commercial platform. BD hired Edwards Lifesciences quality veteran Gary Sorsher to lead global quality, per The Healthcare Technology Report — a modest talent flow signal.
Financial Analysis
The Simply Wall St. thesis — that broader TAVR coverage rewrites Edwards' investment narrative — captures the buy-side reflex: expand indication, expand TAM, expand multiple. The clinical reality is more constrained. The 65–70 age cohort is the meaningful growth tranche, and it sits squarely in the ESC 2025 SAVR-preferred zone. Any Edwards upside from coverage expansion depends on PROGRESS (moderate AS) and EARLY TAVR cost-effectiveness data reading positive at TCT. Neither is a given. BSX's 36% six-month decline reflects headwinds unrelated to structural heart — a reminder that valve exposure is one input among many in these diversified names.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $85.56, +1.41% on the day, +2.39% over six months
- Market cap $49.3B; trailing P/E 50.93, forward P/E 25.34; beta 0.85
- 52-week range $72.30–$96.29
- Analyst consensus buy; target $100.96 (range $84–$110, n=26)
- Next earnings Oct 29, 2026; EPS est $0.74, revenue est $1.68B
Institutional accumulation continues (Corient's 227,947-share buy) as the CMS coverage story circulates. Valuation still prices in TAM expansion that TCT data must actually validate.
Medtronic (MDT)
- Close $92.96, +2.20% on the day, +7.17% over six months
- Market cap $118.9B; trailing P/E 22.9, forward P/E 14.52; beta 0.57
- 52-week range $73.31–$106.33
- Analyst consensus buy; target $104.76 (range $85–$121, n=25)
- Next earnings Nov 17, 2026; EPS est $1.33, revenue est $9.48B
Evolut share and PFA optionality remain the twin drivers. Long-duration low-risk TAVR data from Evolut Low Risk continues to support the structural heart franchise.
Abbott (ABT)
- Close $103.12, +1.15% on the day, -4.95% over six months
- Market cap $178.4B; trailing P/E 33.37, forward P/E 17.0; beta 0.59
- 52-week range $81.97–$137.49
- Analyst consensus buy; target $120.26 (range $103–$135, n=25)
- Next earnings Oct 14, 2026; EPS est $1.42, revenue est $12.99B
MitraClip's TEER franchise faces the sex-disparity NIS data head-on. TriClip's positioning depends heavily on the CLASP II TR PASCAL readout at TCT — a competitor win narrows Abbott's tricuspid moat.
Boston Scientific (BSX)
- Close $44.69, +3.99% on the day, -35.96% over six months
- Market cap $64.8B; trailing P/E 18.09, forward P/E 13.03; beta 0.57
- 52-week range $42.20–$105.65
- Analyst consensus buy; target $62.41 (range $44–$94, n=29)
- Next earnings Oct 28, 2026; EPS est $0.78, revenue est $5.21B
Trading near 52-week lows after the six-month drawdown; today's bounce is technical, not fundamental. Structural heart contribution is modest relative to EP and peripheral franchises.
Anteris Technologies (AVR.AX)
- Close A$11.54, +1.23% on the day, +35.76% over six months
- Market cap A$1.1B; forward P/E -5.33 (unprofitable); 52-week range A$5.20–A$15.47
- Single-analyst target A$13.00; no consensus recommendation
DurAVR THV early clinical data continues to drive the momentum. Cash burn and dilution risk remain the binding constraints for a single-product company.
Market outlook: The six-month divergence between MDT (+7%), EW (+2%), ABT (-5%), and BSX (-36%) tells the story of a sector where structural heart is a differentiator, not a rising tide. TCT 2026 is the near-term catalyst that matters most — PROGRESS, PASCAL vs medical for TR, and ENCIRCLE 2-year each map to specific ticker exposures. Position accordingly.
Clinical Trial Updates
The TCT 2026 late-breaker schedule is the field's next inflection point. Structural heart trials to circle: PROGRESS (TAVR vs surveillance for moderate AS, NEJM); TRAVEL III (LuX-Valve Plus TTVR vs medical therapy, Circulation); CLASP II TR (PASCAL TR repair vs medical therapy, NEJM); ENCIRCLE 2-year (percutaneous TMVR); DUOTAP (routine post-dilation for balloon-expandable TAVR); PROTEMBO IDE (cerebral protection, final); SINGLE-CLOSURE (one vs two ProGlide for transfemoral TAVR); EARLY TAVR cost-effectiveness; and JENA-VAD (Trilogy TAVR for AR in LVAD patients). If PROGRESS misses, the moderate-AS expansion narrative deflates.
Also Filed
A National Inpatient Sample analysis in Cardiology Research found in-hospital AMI in 2.5% of obese patients undergoing TAVR (vs 2.7% non-obese; p=0.295), with AMI raising mortality nearly 5-fold (3.8% vs 0.8%). Anemia, fluid/electrolyte disorders, and weight loss emerged as modifiable pre-procedural targets. Administrative data caveats apply. A separate Structural Heart editorial argues that nonfatal complications must factor into procedural success definitions for TAVR — an overdue reframing as volumes climb and mortality plateaus near single digits.
Looking ahead: Six weeks to TCT 2026. Every valve section of this newsletter will be rewritten by what happens in San Diego between October 31 and November 3. Plan accordingly.